MedTrace Logo

CAR-NK Targeted CD19 for r/r B-cell Malignancies

NCT05645601 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-12-09

No results posted yet for this study

Summary

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies. JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor

Conditions

  • Adult Relapsed/Refractory B-cell Hematologic Malignancies

Interventions

BIOLOGICAL

CD19-CAR-NK

The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy.

Sponsors & Collaborators

  • Beijing JD Biotech Co. LTD.

    collaborator UNKNOWN

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-05-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645601 on ClinicalTrials.gov